FDA advisory committee recommends Novo TTF-100A for Glioblastoma

The FDA Neurological Devices Advisory Panel of the Medical Devices Advisory Committee voted (7 yes; 3 no; 2 abstain) that for patients with supra-tentorial glioblastoma multiforme (GBM) tumors that recur after maximal surgical and radiation treatments, there is reasonable assurance that the benefits of the NovoTTF-100A System (NovoTTF) from Novocure, outweigh its risks when administered as a monotherapy in place of standard medical therapy.